
    
      Durvalumab will be supplied in glass vials containing 500 mg of liquid solution at a
      concentration of 50 mg/mL for intravenous (IV) administration. Durvalumab will be
      administered at 1500 mg (fixed dose) every 4 weeks until disease progression, death,
      unacceptable toxicity or withdrawal of consent for a maximum of 12 months of therapy.
    
  